No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas

Karen T. Barker, Hayley E. Spendlove, Nassera S. Banu, Julia A. Bridge, Cyril Fisher, Janet Shipley, Michelle Garrett, Isaac Manyonda, Richard S. Houlston

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Germline mutations in Fumarate Hydratase (FH) cause the development of leiomyomas and leiomyosarcomas in the syndromes Multiple Cutaneous and Uterine Leiomyomata (MCUL1) and Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). There is little evidence, however, that FH mutation plays a role in the development of sporadic leiomyomas or leiomyosarcomas. Such observations do not, however, exclude a role for FH in tumour development outside the context of MCUL1/HLRCC, as it is possible that FH expression could be silenced by epigenetic mechanisms. To explore this possibility we have developed a highly specific antibody to FH and analysed a series of forty-five fresh-frozen uterine leiomyomas and nine leiomyosarcomas for FH expression.

Original languageEnglish (US)
Pages (from-to)136-140
Number of pages5
JournalCancer Letters
Volume235
Issue number1
DOIs
StatePublished - Apr 8 2006

Fingerprint

Fumarate Hydratase
Leiomyosarcoma
Leiomyoma
Epigenomics
Germ-Line Mutation
Mutation
Antibodies

Keywords

  • Fumarate hydratase
  • Leiomyoma
  • Leiomyosarcoma
  • Western blotting

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Barker, K. T., Spendlove, H. E., Banu, N. S., Bridge, J. A., Fisher, C., Shipley, J., ... Houlston, R. S. (2006). No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas. Cancer Letters, 235(1), 136-140. https://doi.org/10.1016/j.canlet.2005.04.017

No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas. / Barker, Karen T.; Spendlove, Hayley E.; Banu, Nassera S.; Bridge, Julia A.; Fisher, Cyril; Shipley, Janet; Garrett, Michelle; Manyonda, Isaac; Houlston, Richard S.

In: Cancer Letters, Vol. 235, No. 1, 08.04.2006, p. 136-140.

Research output: Contribution to journalArticle

Barker, KT, Spendlove, HE, Banu, NS, Bridge, JA, Fisher, C, Shipley, J, Garrett, M, Manyonda, I & Houlston, RS 2006, 'No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas', Cancer Letters, vol. 235, no. 1, pp. 136-140. https://doi.org/10.1016/j.canlet.2005.04.017
Barker KT, Spendlove HE, Banu NS, Bridge JA, Fisher C, Shipley J et al. No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas. Cancer Letters. 2006 Apr 8;235(1):136-140. https://doi.org/10.1016/j.canlet.2005.04.017
Barker, Karen T. ; Spendlove, Hayley E. ; Banu, Nassera S. ; Bridge, Julia A. ; Fisher, Cyril ; Shipley, Janet ; Garrett, Michelle ; Manyonda, Isaac ; Houlston, Richard S. / No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas. In: Cancer Letters. 2006 ; Vol. 235, No. 1. pp. 136-140.
@article{1b43d895ba1e413686008d730bb3ac4e,
title = "No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas",
abstract = "Germline mutations in Fumarate Hydratase (FH) cause the development of leiomyomas and leiomyosarcomas in the syndromes Multiple Cutaneous and Uterine Leiomyomata (MCUL1) and Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). There is little evidence, however, that FH mutation plays a role in the development of sporadic leiomyomas or leiomyosarcomas. Such observations do not, however, exclude a role for FH in tumour development outside the context of MCUL1/HLRCC, as it is possible that FH expression could be silenced by epigenetic mechanisms. To explore this possibility we have developed a highly specific antibody to FH and analysed a series of forty-five fresh-frozen uterine leiomyomas and nine leiomyosarcomas for FH expression.",
keywords = "Fumarate hydratase, Leiomyoma, Leiomyosarcoma, Western blotting",
author = "Barker, {Karen T.} and Spendlove, {Hayley E.} and Banu, {Nassera S.} and Bridge, {Julia A.} and Cyril Fisher and Janet Shipley and Michelle Garrett and Isaac Manyonda and Houlston, {Richard S.}",
year = "2006",
month = "4",
day = "8",
doi = "10.1016/j.canlet.2005.04.017",
language = "English (US)",
volume = "235",
pages = "136--140",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas

AU - Barker, Karen T.

AU - Spendlove, Hayley E.

AU - Banu, Nassera S.

AU - Bridge, Julia A.

AU - Fisher, Cyril

AU - Shipley, Janet

AU - Garrett, Michelle

AU - Manyonda, Isaac

AU - Houlston, Richard S.

PY - 2006/4/8

Y1 - 2006/4/8

N2 - Germline mutations in Fumarate Hydratase (FH) cause the development of leiomyomas and leiomyosarcomas in the syndromes Multiple Cutaneous and Uterine Leiomyomata (MCUL1) and Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). There is little evidence, however, that FH mutation plays a role in the development of sporadic leiomyomas or leiomyosarcomas. Such observations do not, however, exclude a role for FH in tumour development outside the context of MCUL1/HLRCC, as it is possible that FH expression could be silenced by epigenetic mechanisms. To explore this possibility we have developed a highly specific antibody to FH and analysed a series of forty-five fresh-frozen uterine leiomyomas and nine leiomyosarcomas for FH expression.

AB - Germline mutations in Fumarate Hydratase (FH) cause the development of leiomyomas and leiomyosarcomas in the syndromes Multiple Cutaneous and Uterine Leiomyomata (MCUL1) and Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). There is little evidence, however, that FH mutation plays a role in the development of sporadic leiomyomas or leiomyosarcomas. Such observations do not, however, exclude a role for FH in tumour development outside the context of MCUL1/HLRCC, as it is possible that FH expression could be silenced by epigenetic mechanisms. To explore this possibility we have developed a highly specific antibody to FH and analysed a series of forty-five fresh-frozen uterine leiomyomas and nine leiomyosarcomas for FH expression.

KW - Fumarate hydratase

KW - Leiomyoma

KW - Leiomyosarcoma

KW - Western blotting

UR - http://www.scopus.com/inward/record.url?scp=33645851364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645851364&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2005.04.017

DO - 10.1016/j.canlet.2005.04.017

M3 - Article

C2 - 15949892

AN - SCOPUS:33645851364

VL - 235

SP - 136

EP - 140

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -